medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2022, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2022; 69 (1)

Relative frequency report on bacterial infections associated with HAI, analysis from 2019 to 2021 of a Third Level Hospital

Sánchez GJM, Rodríguez AEA, Rivera CAE, Portillo GJH, Jiménez URA, Ramírez BÉJ, Silva MAM, Hernández AF, Franco SR, Aguirre RIY

Language: Spanish
References: 19
Page: 11-17
PDF size: 267.32 Kb.


ABSTRACT

Introduction: the epidemiological and microbiological characterization of infections associated with health care (IAAS), as well as a precision antibiogram, is essential today to stop the growing advance of antimicrobial resistance (AMR), which is one of the leading causes of death worldwide, with the greatest burdens in low-resource settings further increasing the cost of care and hospital days. Material and methods: an observational, retrolective, longitudinal panel and comparative analysis of three years (2019 to 2021) was carried out in records of 1,940 patients who received treatment for HAIs during their stay in a private hospital. Relative frequencies of the isolated bacteria. Results: the age was found with a global average of 50.61 years and a SD ± 24.55 years, 54% of the cases were male and 46% female, without statistical significance. 112 bacteria of clinical interest were found (63% Gram negative and 36.4% Gram positive), with an RF greater than 0.006, of which 15 bacteria were selected per year, finding 4 bacteria in the first two years and 5 bacteria in the last year, defined as group 1 priority by the WHO, 1 bacterium in the three years defined in group 2 and an emerging bacterium (Stenotrophomonas maltophilia), with recently reported multiresistance characteristics. Conclusion: the country's clinical laboratories should use the latest generation diagnostic techniques and, where appropriate, seek financing mechanisms for their updating and achieve access to standardized and quality studies for the entire population, in order to reduce the effect of AMR on public health, directing the best therapy, because HAIs are a dynamic phenomenon over time, even within the same hospital. We must consider interdisciplinary work in microbiology as the best way to achieve "One Health".


REFERENCES

  1. Organización Panamericana de la Salud. Tratamiento de las enfermedades infecciosas 2020-2022. 8va edición. Vol. 112, La Semana médica. Washington, D.C.; 2019. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/51695/9789275321133_spa.pdf?sequence=9&isAllowed=y

  2. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. pp. 1-113. Available in: https://www.cdc.gov/drugresistance/biggest_threats.htm

  3. OMS Resistencia a los antimicrobianos 2020. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/antimicrobial-resistance

  4. Patógenos multirresistentes que son prioritarios para la OMS 4 Mar 2021. Disponible en: https://www.paho.org/es/noticias/4-3-2021-patogenos-multirresistentes-que-son-prioritarios-para-oms

  5. CDC. Antibiotic resistance threats in the United States, 2019. Dep Heal Hum Serv. 2019; 1–113. Available in: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

  6. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26 (12): 1622-1629.

  7. Organización Mundial de la Salud. Plan de acción mundial sobre la resistencia a los antimicrobianos [Internet]. Ginebra: Organización Mundial de la Salud; 2016, p. 30. [Citado 8 de mayo de 2022]. Disponible en: https://apps.who.int/iris/handle/10665/255204.

  8. Benic MS, Milanic R, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A et al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. J Antimicrob Chemother. 2018; 73: 50-58.

  9. Jiménez PMA, Galas M, Corso A, Hormazábal JC, Duarte VC, Salgado MN et al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes. Rev Panam Salud Pública .2019; 43: e65. doi: 10.26633/RPSP.2019.65.

  10. Semana mundial de concienciación sobre el uso de los antimicrobianos 2020. [Acceso 9 mayo de 2022] Disponible en: https://www.who.int/es/news-room/events/detail/ 2020/11/18/default-calendar/world-antimicrobial-awareness-week- 2020#:~:text=El%20Comit%C3%A9%20Ejecutivo%20de%20la,aplicar%C3%A1%20a%20todos%20los%20sectores

  11. Giono-Cerezo S, Santos-Preciado JI, Morfín-Otero MR, Torres-López FJ, Alcántar-Curiel MD. Resistencia antimicrobiana. Importancia y esfuerzos por contenerla. Gac. Méd. Méx. 2020; 156 (2): 172-180. Disponible en: https://doi.org/10.24875/gmm.20005624

  12. Alós JI. Resistencia bacteriana a los antibióticos: una crisis global. Enfermedades Infecciosas y Microbiología Clínica. 2015; 33 (10): 692-699. doi: 10.1016/j.eimc.2014.10.004.

  13. Consejo de Salubridad General,. "Acuerdo por el que se declara la obligatoriedad de la estrategia nacional de acción contra la resistencia a los antimicrobianos. Diario Oficial de la Federación. México, 2018. [Citado en junio 2022]. Disponible en: https://scholar.google.com/scholar_lookup?title=+Acuerdo+por+el+que+se+declara+la+obligatoriedad+de+la+Estrategia+Nacional+de+Acci%C3%B3n+contra+la+Resistencia+a+los+Antimicrobianos&publication_year=2018#d=gs_cit&t=1659760797901&u=%2Fscholar%3Fq%3Dinfo%3At8pLxyPpf_0J%3Ascholar.google.com%2F%26output%3Dcite%26scirp%3D0%26hl%3Des.

  14. Camacho-Silvas LA, Portillo-Gallo JH, Rivera-Cisneros AE, Sánchez-González JM, Franco-Santillán R et al. Multidrug, extended and pan-resistance to antimicrobials at the North of México. Cir Cir. 2021; 89 (4): 426-434. doi: 10.24875/CIRU.20000304.

  15. Álvarez MM, Giménez PM, Reynaga E, Carabias AL, Mòdol DJM. Novedades en la duración recomendada de los tratamientos antibióticos. Terapéutica en APS. 2020; 27 (5): 247-253. doi: 10.1016/j.fmc.2019.09.01.

  16. OMS, Sistema mundial de vigilancia de la resistencia a los antimicrobianos (GLASS) Disponible en: http://apps.who.int/iris/bitstream/handle/10665/253135/9789243549408-spa.pdf;jsessionid=4B52E935EA1BAFD09735ABF3089E4D76?sequence=1

  17. Murray CJL, Shunji IK, Sharara F, Swetschinski L, Robles AG, Gray A et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2019; 399 (10325): 629-655. doi: https://doi.org/10.1016/S0140-6736(21)02724-0.

  18. Portillo-Gallo JH, Sánchez-González JM, Velo-Méndez G, Rivera Cisneros AE et al. Acinetobacter baumannii panresistente en paciente post-COVID-19 y comorbilidades. Rev Mex Patol Clin Med Lab. 2021; 68 (3): 137-139. doi: 10.35366/105031.

  19. Dreser MA. La resistencia antimicrobiana desde el enfoque de Una Salud. INSP. Disponible en: https://www.espm.mx/blog/resistencia-antimicrobiana-enfoque-una-salud/. Acceso 20 mayo 2022.




2020     |     www.medigraphic.com